Trial
NCT01518465
Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Southern California
Collaborators
National Cancer Institute (NCI); Celgene Corporation
Condition
Stage I Multiple Myeloma
Intervention
dalteparin
Why stopped
Insufficient Accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-11-29